List of Excipients in Branded Drug ZINC CHLORIDE

Generic Drugs Containing ZINC CHLORIDE

Company	Ingredient	NDC	Excipient
Exela Pharma SciencesLLC	zinc chloride	51754-0102	SODIUM CHLORIDE
Somerset Therapeutics LLC	zinc chloride	70069-526	HYDROCHLORIC ACID
Somerset Therapeutics LLC	zinc chloride	70069-526	SODIUM CHLORIDE
Somerset Therapeutics LLC	zinc chloride	70069-526	SODIUM HYDROXIDE
Somerset Therapeutics LLC	zinc chloride	70069-526	WATER

What are the Most Frequently-Used Excipients in ZINC CHLORIDE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
2	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Zinc Chloride Excipient Strategy and Commercial Opportunities in Pharmaceutical Products

Last updated: August 3, 2026

Zinc chloride is primarily a pharmaceutical active ingredient and trace-element source, not a mainstream excipient. Its strongest commercial opportunity is in parenteral nutrition, especially sterile zinc chloride injections used as additives to total parenteral nutrition. Excipient opportunities exist in topical, dental, oral, and specialty delivery systems, but they are constrained by zinc chloride’s acidity, high chloride content, reactivity with phosphates and proteins, and concentration-dependent tissue irritation.

The most defensible strategy is to position zinc chloride around formulation performance, sterile supply reliability, pediatric dosing, compatibility data, and ready-to-use delivery rather than around the commodity API alone.

What pharmaceutical products contain zinc chloride?

Zinc chloride is used in several pharmaceutical categories:

Product category	Primary role of zinc chloride	Commercial relevance
Parenteral nutrition	Source of elemental zinc	Highest-value regulated drug opportunity
Topical products	Astringent, protein precipitant, antiseptic or tissue-tightening agent	Niche, formulation-sensitive
Dental products	Astringent, desensitizing or tissue-management ingredient	Specialty opportunity
Oral formulations	Zinc source or functional antimicrobial ingredient	Limited by taste, irritation and dose control
Laboratory and compounding products	Reagent or formulation component	Lower regulatory and margin profile
Advanced delivery systems	Zinc ion source, crosslinking or antimicrobial component	Potentially patentable, but technically complex

Zinc chloride contains approximately 48% elemental zinc by weight. A 1 mg/mL zinc chloride injection therefore provides approximately 0.48 mg/mL of elemental zinc, subject to the labeled salt concentration and product specification.

The primary FDA-recognized drug use is zinc supplementation in parenteral nutrition. FDA-approved zinc chloride injection labeling describes the product as an additive to intravenous solutions for preventing zinc deficiency in patients receiving parenteral nutrition.[1]

What is the FDA regulatory status of zinc chloride injection?

Zinc chloride injection is regulated as a prescription drug when supplied for intravenous use. The product is not administered directly as an undiluted injection. It is added to a compatible parenteral nutrition solution under controlled compounding conditions.[1]

Key regulatory characteristics include:

Regulatory element	Zinc chloride injection
FDA pathway	Approved prescription drug products and abbreviated applications may apply depending on product and sponsor
Therapeutic category	Trace-element supplementation and parenteral nutrition
Route	Intravenous after dilution into a suitable solution
Dosage form	Sterile injectable solution or concentrate
Preservative profile	Usually preservative-free for parenteral nutrition use
Primary users	Hospitals, home-infusion providers, neonatal units and compounding pharmacies
Critical controls	Sterility, endotoxin, particulate matter, assay, elemental zinc content and container compatibility
Main regulatory risk	Administration error, precipitation, incompatibility and manufacturing contamination

The product must be evaluated under parenteral drug quality standards, including sterile manufacturing, container-closure integrity, particulate control, extractables and leachables, and validated stability.

FDA labeling warns that zinc chloride is irritating to tissues at concentrated levels and must be diluted before administration.[1] This characteristic limits its use as a direct injectable product but creates a commercial opportunity for safe, standardized premixes.

What excipient strategy is appropriate for zinc chloride?

Zinc chloride should not usually be treated as an inert excipient. In most pharmaceutical applications, it has a pharmacological, nutritional, antimicrobial or tissue-reactive function. The correct development classification depends on the product claim and concentration.

Zinc chloride as an active ingredient

This is the strongest regulatory position when zinc chloride supplies elemental zinc or produces a therapeutic effect. Examples include:

• Parenteral zinc supplementation.
• Zinc-containing oral products.
• Topical astringent products.
• Dental preparations with tissue-management or antimicrobial claims.

The sponsor must establish the amount of zinc chloride and elemental zinc, control impurities, justify the dosage, and demonstrate product safety for the intended route.

Zinc chloride as a functional excipient

Zinc chloride may be used as a functional formulation component where it contributes to:

• Ionic crosslinking of polymers.
• Antimicrobial activity.
• Protein precipitation.
• Astringency.
• Modification of gel strength or release rate.
• Stabilization of selected formulations through ionic interactions.

This strategy is more difficult because the ingredient may still be considered an active component by regulators if it contributes materially to the product’s clinical effect. A sponsor cannot reliably avoid active-ingredient obligations simply by labeling zinc chloride an excipient.

Zinc chloride as a processing aid

The lowest-risk use is as a manufacturing reagent that is removed or reduced to a controlled residual level before the finished product is released. This approach may apply to biomaterials, polymeric systems or purification processes. The sponsor must validate removal and establish residual acceptance criteria.

Which formulations are protected by zinc chloride’s technical properties?

Parenteral nutrition formulations

Parenteral nutrition is the most established opportunity. Zinc chloride can be supplied as a concentrated sterile solution for addition to amino acids, dextrose, lipid emulsions or multi-trace-element preparations.

The development focus should be compatibility rather than simple assay.

Important compatibility risks include:

• Precipitation with phosphate.
• Interaction with calcium and magnesium.
• Complexation with amino acids.
• Adsorption to container surfaces.
• Reaction with sulfide-containing compounds.
• pH shifts in multi-component nutrition admixtures.
• Increased particulate formation during extended storage.
• Loss of zinc through tubing or container interaction.

A product developer should build a formulation matrix covering clinically relevant concentrations, storage temperatures, container materials, admixture sequences and hold times. Compatibility data can become a commercial differentiator even when the zinc chloride molecule itself is unprotectable.

Topical gels, creams and solutions

Zinc chloride can produce astringency and antimicrobial effects, but concentrated solutions can cause irritation and tissue damage. The formulation must control local zinc activity rather than only total zinc concentration.

Potential vehicles include:

• Hydrogels.
• Mucoadhesive oral gels.
• Aqueous wound solutions.
• Alcohol-free topical solutions.
• Polymer films.
• Sprayable systems.
• Dental pastes and barrier formulations.

The strongest product concepts are those that control release and reduce peak tissue exposure. Polymer complexation, liposomal delivery and in situ gelation may provide technical differentiation, but the sponsor must prove that the delivery system improves tolerability or clinical performance.

Oral solid and liquid formulations

Zinc chloride is less attractive than several other zinc salts for conventional oral products because of its metallic taste, hygroscopicity and potential gastric irritation. It may still be useful where the product requires:

• High solubility.
• Rapid ion release.
• A concentrated liquid dose.
• Combination with antimicrobial or astringent claims.
• A low-volume dosage form.

Taste masking, chelation control and packaging against moisture are the main formulation requirements.

Dental formulations

Dental products may use zinc chloride for astringent, antimicrobial or tissue-management purposes. Commercial formats could include:

• Dental gels.
• Gingival solutions.
• Root-canal adjuncts.
• Desensitizing preparations.
• Professional-use tissue retraction systems.
• Controlled-release periodontal inserts.

The principal technical barrier is achieving useful local activity without damaging mucosal or dental tissue. Dental products also face a classification question: cosmetic, OTC drug, professional-use device or prescription product.

How many patents cover zinc chloride?

The zinc chloride molecule is old and cannot support a new composition-of-matter patent. Commercial protection must come from the product architecture.

Potential protection layer	Patent potential	Typical claim focus
Zinc chloride molecule	None for the established compound	Not available as new chemical matter
Purity specification	Low to moderate	Impurity profile and manufacturing process
Sterile injectable composition	Moderate	Concentration, pH, excipient system and stability
Parenteral nutrition admixture	Moderate	Compatibility, sequencing and storage conditions
Topical delivery system	Moderate to high	Polymer matrix, controlled release and tissue tolerability
Dental formulation	Moderate	Localized delivery, release and use method
Device or packaging	Moderate	Ready-to-use container, mixing system or dosing architecture
Manufacturing process	Moderate	Purification, crystallization, sterile filtration or filling
Method of treatment	Moderate, jurisdiction-dependent	Dosing, patient population or nutritional indication

A strong zinc chloride patent estate would normally combine formulation claims, manufacturing claims, container or device claims, and method-of-use claims. A single broad claim to “zinc chloride in a pharmaceutical composition” would face serious validity and prior-art risks.

Patent strength is likely to be highest for a product that demonstrates a measurable technical effect, such as:

• Reduced precipitation in parenteral nutrition.
• Extended admixture stability.
• Lower tissue irritation at equivalent zinc exposure.
• Improved zinc bioavailability.
• Reduced container adsorption.
• Improved neonatal dosing accuracy.
• Reduced compounding errors.

When does zinc chloride lose exclusivity?

Zinc chloride has no meaningful compound patent exclusivity because it is an established inorganic salt. Exclusivity depends on the specific product and jurisdiction.

For U.S. products, the relevant barriers may include:

Exclusivity or barrier	Effect
Compound patent	Generally unavailable
Formulation patent	May delay copying if listed or enforceable
Method-of-use patent	May affect labeled use but often has limited commercial reach
Manufacturing patent	Can raise switching costs but may be designed around
Regulatory exclusivity	Depends on the approved application and designation
Trade secrets	Can protect process and compatibility know-how
Quality file and supply qualification	Can delay substitution without creating legal exclusivity

For an established zinc chloride injection, generic entry can occur rapidly if the reference product has no enforceable patents or unexpired regulatory protections. The commercial value of exclusivity therefore comes from regulatory execution, supply contracts, validated quality systems and differentiated presentation.

What is the Orange Book status of zinc chloride?

The FDA Orange Book must be reviewed by product-specific application number and dosage form. Zinc chloride is not protected as a molecule, and an Orange Book listing for one injectable presentation would not automatically protect topical, oral, dental or nutrition-admixture products.

The main Orange Book questions are:

1. Is the reference product listed as an approved prescription drug?
2. Does the product have unexpired patents listed by the application holder?
3. Is there regulatory exclusivity remaining?
4. Are the patents directed to the product, formulation or method of use?
5. Can an ANDA applicant certify that the product does not infringe?

A zinc chloride sponsor should not assume that a patent covering a sterile injectable concentrate protects a ready-to-use parenteral nutrition bag or a topical gel. Those products may require separate claims and separate regulatory strategies.

Which companies are challenging zinc chloride products?

Generic competition is more likely than branded patent litigation. Zinc chloride injection is a low-complexity active ingredient, but sterile injectable manufacturing creates practical entry barriers.

Potential competitors include:

• Established injectable manufacturers.
• Parenteral nutrition suppliers.
• Hospital-compounding networks.
• Contract manufacturers with sterile fill-finish capacity.
• Multi-trace-element product suppliers.
• Regional generic-drug companies.

The highest competitive risk is likely to come from companies that already have:

• FDA-inspected sterile facilities.
• Validated small-volume parenteral lines.
• Existing hospital contracts.
• Established parenteral nutrition portfolios.
• Access to qualified zinc chloride API.
• Strong shortage-response capabilities.

What Paragraph IV challenges are likely for zinc chloride?

Paragraph IV risk depends on whether a reference product has unexpired Orange Book-listed patents. For a mature zinc chloride injectable, the baseline risk is usually high because:

• The active ingredient is old.
• The dosage form is conventional.
• The therapeutic use is established.
• Alternative sterile presentations may be readily developed.
• Formulation patents may be narrow.

A generic applicant could challenge patents covering:

• Zinc chloride concentration.
• pH range.
• Sterile injectable composition.
• Container-closure system.
• Admixture stability.
• Specific parenteral nutrition uses.

The reference sponsor’s strongest response would be a focused formulation patent supported by comparative data. Generic applicants may also pursue non-infringement positions by changing the concentration, container, pH, labeling or admixture instructions.

What patent litigation affects zinc chloride?

There is no well-known branded patent dispute comparable to major small-molecule blockbusters involving zinc chloride as the active ingredient. Litigation risk is more likely to arise from:

• ANDA filings against a specific injectable reference product.
• Claims covering sterile manufacturing.
• Ready-to-use parenteral nutrition products.
• Combination trace-element formulations.
• Topical delivery systems.
• Medical-device or container claims.
• Trade-secret disputes involving purification or fill-finish processes.

The absence of major litigation does not mean that a new formulation is unprotectable. It means that the commercial case must be based on differentiated product performance rather than expected enforcement of a compound patent.

What manufacturing and IP barriers exist?

API manufacturing

Zinc chloride is inexpensive and widely available. The basic manufacturing process does not create a durable market barrier. Pharmaceutical-grade supply must meet requirements for:

• Assay and elemental zinc content.
• Heavy metals and elemental impurities.
• Chloride and sulfate impurities.
• Insoluble matter.
• Water content.
• Microbial quality where applicable.
• GMP documentation.
• Lot traceability.

For parenteral use, the drug-product manufacturing process is more important than the commodity API process.

Sterile fill-finish

Sterile production is a meaningful barrier. The sponsor must control:

• Bioburden before sterilizing filtration.
• Endotoxin.
• Particles.
• Filter compatibility.
• Container-closure integrity.
• Aseptic process simulation.
• Zinc adsorption and leachables.
• Stability after terminal manipulation or admixture.

A sponsor with a qualified sterile facility can gain practical market share even without patent exclusivity.

Container and packaging

Zinc chloride solutions may interact with glass, elastomers, plastics and metal components. Packaging development should compare:

• Type I glass.
• Polymer vials.
• Prefilled syringes where clinically appropriate.
• Small-volume bags.
• Ampoules.
• Dual-chamber or mixing systems.
• Low-sorbing tubing and connectors.

Packaging claims may support a secondary patent estate if they solve a demonstrated stability or dosing problem.

What licensing deals are available around zinc chloride?

Zinc chloride itself is unlikely to command a conventional molecule-license transaction. More realistic licensing opportunities concern delivery platforms and commercial infrastructure.

Potential deal structures include:

Asset	Likely transaction
Sterile zinc chloride injectable	Regional commercialization or supply agreement
Ready-to-use nutrition admixture	Co-development and hospital-channel license
Topical controlled-release gel	Formulation license with milestone payments
Dental product	Territory-based license to a dental company
Polymer or hydrogel platform	Field-limited license
Container or mixing device	Bundled device-drug commercialization agreement
Qualified API source	Long-term supply and capacity reservation

The most valuable licensable asset is likely to be a validated product with regulatory approval, shortage-resilient manufacturing and hospital formulary adoption. A license based only on zinc chloride API access would have limited bargaining power.

How does zinc chloride compare with other zinc salts?

Zinc salt	Main advantages	Main disadvantages	Best-fit products
Zinc chloride	High solubility and rapid zinc-ion release	Irritating, acidic, hygroscopic and reactive	Injectable nutrition, specialty topical products
Zinc sulfate	Established and inexpensive	Taste, gastrointestinal effects and crystallization concerns	Oral supplements, some topical products
Zinc gluconate	Better oral acceptability	Lower zinc content by weight	OTC oral supplements
Zinc acetate	Useful oral tolerability and solubility profile	Taste and formulation limitations	Oral products
Zinc oxide	Stable and low-cost	Poor water solubility	Topical barriers and creams
Zinc pyrithione	Antimicrobial history	Regulatory restrictions and safety scrutiny	Limited specialty uses

Zinc chloride’s strategic advantage is solubility. Its strategic weakness is reactivity. The best commercial applications are those that require rapid availability of zinc ions and can control local exposure.

What generic launch scenarios exist?

Scenario 1: Conventional sterile concentrate

This is the most exposed product. If the reference product has no enforceable patents, an ANDA-based competitor could enter after approval. Price competition would be substantial, and hospital contracts would determine market share.

Scenario 2: Ready-to-use parenteral nutrition presentation

This product has stronger commercial differentiation. The sponsor could compete on reduced compounding steps, lower contamination risk, neonatal dose accuracy and pharmacy labor savings. Regulatory requirements and manufacturing complexity would also be higher.

Scenario 3: Multi-trace-element combination

Combining zinc chloride with other trace elements could increase clinical utility but would create compatibility, stability and regulatory complexity. Patents may protect a specific composition, but prior-art and obviousness risks would remain significant.

Scenario 4: Controlled-release topical or dental product

A differentiated delivery system could support formulation and method-of-use patents. Commercial success would depend on tolerability, clinical evidence and the product’s regulatory classification.

What is the revenue exposure for zinc chloride products?

Revenue exposure is driven less by zinc chloride API cost than by product presentation and channel.

Revenue driver	Impact
Bulk API price	Low
Sterile manufacturing capacity	High
Hospital contracts	High
Shortage status	High but potentially temporary
Ready-to-use presentation	High
Pediatric and neonatal use	Moderate to high
Topical consumer demand	Variable
Patent exclusivity	Usually limited
Regulatory approval	High
Supply reliability	High

A commodity zinc chloride injection is likely to face price pressure. A validated ready-to-use product can capture more value by reducing pharmacy handling, preventing compounding errors and improving availability.

Key Takeaways

1. Zinc chloride is primarily an active pharmaceutical ingredient and trace-element source, not a conventional inert excipient.
2. Parenteral nutrition is the strongest established pharmaceutical market.
3. The molecule has no meaningful new-chemical-matter patent opportunity.
4. Formulation, packaging, admixture compatibility, manufacturing and dosing systems provide the main IP opportunities.
5. Sterile fill-finish capability is a more important commercial barrier than API supply.
6. Generic and Paragraph IV risks are high for conventional zinc chloride injections without enforceable product patents.
7. Ready-to-use nutrition products, pediatric presentations and controlled-release topical or dental systems offer the strongest differentiation.
8. Biosimilar risk does not apply because zinc chloride is an inorganic small-molecule salt, not a biologic.
9. Licensing value is likely to attach to delivery systems, regulatory approvals, supply capacity and hospital-channel access.
10. The best strategy is to sell verified compatibility, safety and workflow benefits rather than zinc chloride as a commodity ingredient.

FAQs

Is zinc chloride approved for intravenous use?

Yes. Zinc chloride injection is used as a source of zinc in parenteral nutrition after dilution into an appropriate intravenous solution.[1]

Can zinc chloride be used as an inactive ingredient?

It can be used as a functional formulation component, but its regulatory status depends on whether it contributes to the product’s therapeutic, antimicrobial, astringent or nutritional effect. In many products it will be treated as an active ingredient rather than an inert excipient.

Does zinc chloride have biosimilar competition?

No. Biosimilar regulation applies to biological products. Zinc chloride is an inorganic salt and is exposed primarily to generic-drug and formulation competition.

What is the strongest patent strategy for zinc chloride?

The strongest strategy combines formulation claims with compatibility, controlled-release, packaging, manufacturing and method-of-use claims supported by comparative performance data.

Is zinc chloride more commercially attractive than zinc gluconate?

Zinc chloride is more soluble and better suited to rapid zinc-ion delivery and injectable nutrition. Zinc gluconate is generally more suitable for oral consumer products because of better tolerability and market familiarity.

References

1. U.S. Food and Drug Administration. (2023). Zinc chloride injection, USP: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. United States Pharmacopeia. (2024). Zinc chloride monograph. In United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2016). Questions and answers on quality considerations for drug products containing nanomaterials. U.S. Department of Health and Human Services.

5. International Council for Harmonisation. (2023). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/

6. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org/

7. U.S. Food and Drug Administration. (2023). Sterile drug products produced by aseptic processing: Current good manufacturing practice. U.S. Department of Health and Human Services.